0000000000021334

AUTHOR

Angelica Petrillo

showing 6 related works from this author

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

2018

Background: Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival. Methods: We retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions. Full clinical data, including the Prognostic Nutritional Index (PNI), neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio, were analysed in a training cohort of 50 patients. Receiv…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisDerived neutrophil-to-lymphocyte ratio; Head and neck squamous cell carcinoma; Inflammation-based prognostic scores; Neutrophil-to-lymphocyte ratio; Overall survival; Prognostic factors; Prognostic nutritional indexoverall survivalhead and neck squamous cell carcinomaderived neutrophil-to-lymphocyte ratio03 medical and health sciences0302 clinical medicineneutrophil-to-lymphocyte ratioInternal medicinemedicine1506Stage (cooking)Neutrophil to lymphocyte ratioOriginal ResearchUnivariate analysisbusiness.industryHead and neck cancerInduction chemotherapyprognostic factorsprognostic nutritional indexmedicine.diseaseHead and neck squamous-cell carcinomaClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisinflammation-based prognostic scoresbusinessESMO open
researchProduct

Final results of neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in advanced pancreatic cancer patients treated with Nab-paclitaxel plus …

2016

e15737Background: Pancreatic cancer is the ninth most common cancer and the forth cause of cancer-related mortality worldwide. New regimens have increased overall survival, but it still remains ext...

OncologyCancer Researchmedicine.medical_specialtybusiness.industryCancermedicine.diseaseGemcitabineOncologyPancreatic cancerInternal medicineImmunologymedicineOverall survivalNeutrophil to lymphocyte ratiobusinesshuman activitieshealth care economics and organizationsNab-paclitaxelmedicine.drugJournal of Clinical Oncology
researchProduct

Cancer of the Esophagus

2021

In 2015 esophageal cancer (OC) was globally the 11th most common cancer with 483,000 new cases and the 7th most common cause of cancer-related deaths, with 439,000 deaths. Esophageal cancer is a highly lethal disease of older age, sixth to seventh decades, associated with a remarkable decline in health-related quality of life, high mortality, and poor prognosis with an overall 5-year survival no greater than 20%. The two major histological types, squamous cell carcinoma (SCC) and adenocarcinoma (ADC), while sharing the esophageal site, can be considered like two different neoplastic diseases as they differ in their epidemiology, risk factors, pathogenesis, and treatment. Other malignancies …

Oncologymedicine.medical_specialtybusiness.industryCancerEsophageal cancermedicine.diseasemedicine.anatomical_structureInternal medicineCarcinosarcomamedicineCarcinomaAdenocarcinomaSarcomaEsophagusbusinessChemoradiotherapy
researchProduct

Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC)

2017

Oncologymedicine.medical_specialtyPrognostic factorIndex (economics)business.industryHead and neck cancerCellHematologymedicine.diseaseHead and neck squamous-cell carcinomamedicine.anatomical_structureOncologyInternal medicinemedicinebusinessPrognostic Nutritional Index (PNI)
researchProduct

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine…

2018

Background. High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer. Methods. We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy with nab-paclitaxel/gemcitabine at two different European oncologic centers between January 2012 and November 2015. Variables assessed for prognostic correlations included age ≥ 66, sex, Karnofsky PS score, primary tumor site, baseline CA19.9 level ≥ 59xULN, 12-week decrease of the CA19.9 level ≥ 50% from baseline, basal bilirubin level, baseline NLR, biliary stent implantation, and liver metastasis. Survival analyses were generated according…

0301 basic medicinemedicine.medical_specialtyArticle Subjectmedicine.medical_treatmentGastroenterologyMetastasis03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicineNeutrophil to lymphocyte ratiolcsh:RC799-869ChemotherapyHepatologyProportional hazards modelbusiness.industryGastroenterologymedicine.diseasePrimary tumorGemcitabine030104 developmental biology030220 oncology & carcinogenesisPropensity score matchinglcsh:Diseases of the digestive system. Gastroenterologybusinessmedicine.drugResearch ArticleGastroenterology Research and Practice
researchProduct

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Dou…

2021

BackgroundFew data regarding post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC) are available.MethodsThis multicenter, retrospective study aimed at evaluating clinicians’ attitude, and the safety and effectiveness of post-induction strategies in consecutive patients affected by left-sided RAS/BRAF wild-type mCRC treated with doublet chemotherapy plus anti-EGFR as first-line regimen, who did not experience disease progression within 6 months from induction initiation, at 21 Italian and 1 Spanish Institutions. The measured clinical outcomes were: p…

Cancer Researchmedicine.medical_specialtyColorectal cancerPopulationGastroenterologymaintenanceFOLFIRIFOLFOXInternal medicinecetuximabmedicineAdverse effecteducationRC254-282education.field_of_studybusiness.industryMCRCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studymedicine.diseaseRegimenFOLFOXOncologyCohortFOLFIRIbusinesspanitumumabmedicine.drugFrontiers in Oncology
researchProduct